Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817030) titled 'Evaluation of Solanidine as an Exogenous Biomarker to Phenotype CYP2D6 Activity in Humans' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: University Medicine Greifswald
Condition:
Pharmacokinetic Study in Healthy Volunteers
Intervention:
Dietary Supplement: Yohimbine
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: September 21, 2026
Target Sample Size: 30
Countries of Recruitment:
Germany
To know more, visit https://clinicaltri...